Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study

Maturitas

Volumn 67, Issue 3, 2010, Pages 227-232

  Stevenson, John C ^a   Durand, Gemma ^b   Kahler, Elke ^c   Pertyński, Tomasz ^d  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b L'Aigue Marine   (France)

^c ABBOTT GMBH AND CO KG   (Germany)

^d POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Dydrogesterone; Hormone replacement therapy; Oestradiol; Postmenopausal; Ultra low dose; Vasomotor symptoms

Indexed keywords

DYDROGESTERONE; ESTRADIOL; PLACEBO;

ADULT; AGED; ARTICLE; BREAST DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; FEMALE; HEADACHE; HERPES SIMPLEX; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MASTALGIA; MENSTRUATION; METRORRHAGIA; MULTICENTER STUDY; NAUSEA AND VOMITING; PANCREATITIS; PERICARDITIS; POSTMENOPAUSE; QUALITY OF LIFE; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; UTERINE POLYP; UTERUS BLEEDING; UTERUS MYOMA; UTERUS TUMOR;

ADMINISTRATION, ORAL; CONTRACEPTIVES, ORAL, COMBINED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; TREATMENT OUTCOME; VASOMOTOR SYSTEM;

HUMAN ECHOVIRUS 1;

EID: 77958101217     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.07.002     Document Type: Article

References (24)

1. W.H. Utian Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review Health Qual Life Outcomes 3 2005 47 56
2. K. Rödström, C. Bengtsson, L. Lissner, I. Milsom, V. Sundh, and C. Björkelund A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century Menopause 9 2002 156 161
3. North American Menopause Society Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society Menopause 11 2004 11 33
4. N. Santoro Symptoms of menopause: hot flushes Clin Obstet Gynecol 51 2008 539 548
5. North American Menopause Society Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society Menopause 17 2010 242 255
6. Board of the International Menopause Society, A. Pines, and D.W. Sturdee IMS updated recommendations on postmenopausal hormone therapy Climacteric 10 2007 181 194 (Pubitemid 46752441)
7. AACE Menopause Guidelines Revision Task Force American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause Endocr Pract 12 2006 315 337
8. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
9. H.D. Nelson, K.K. Vesco, and E. Haney Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis JAMA 295 2006 2057 2071
10. D. Cheema, A. Coomarasamy, and T. El-Toukhy Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review Arch Gynecol Obstet 276 2007 463 469
11. ® for treatment of menopausal symptoms: dosage comparison study Adv Ther 9 1992 21 31
12. M. Notelovitz, J.P. Lenihan, M. McDermott, I.J. Kerber, N. Nanavati, and J. Arce Initial 17beta-estradiol dose for treating vasomotor symptoms Obstet Gynecol 95 2000 726 731
13. M. Notelovitz, and J.H. Mattox Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol Menopause 7 2000 310 317
14. http://www.fda.gov/cder/foi/label/2003/21396-prempro-lbl.pdf.
15. G.A. Hauser, I.C. Huber, P.J. Keller, C. Lauritzen, and H.P. Schneider Evaluation of climacteric symptoms (Menopause Rating Scale) Zentralbl Gynakol 116 1994 16 23
16. L. Heinemann, P. Potthoff, and H.P. Schneider International versions of the Menopause Rating Scale (MRS) Health Qual Life Outcomes 1 2003 28
17. R.R. Freedman Pathophysiology and treatment of menopausal hot flashes Semin Reprod Med 23 2005 117 125
18. R.R. Freedman, and C.M. Blacker Estrogen raises the sweating threshold in postmenopausal women with hot flashes Fertil Steril 77 2002 487 490
19. V. Beral Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
20. B. Ettinger Rationale for the use of lower estrogen doses for postmenopausal hormone therapy Maturitas 57 2007 81 84
21. O.E. Johansen, and E. Qvigstad Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg Adv Ther 25 2008 525 551
22. N. Panay, O. Ylikorkala, D.F. Archer, R. Gut, and E. Lang Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief Climacteric 10 2007 120 131
23. P.H.M. van de Weijer, L.-A. Mattsson, and O. Ylikorkala Benefits and risks of long-term low-dose oral continuous combined hormone therapy Maturitas 56 2007 231 248
24. C. Quereux, B. Pornel, C. Bergeron, and A. Ferenczy Continuous combined hormone replacement therapy with 1 mg 17β-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile Maturitas 53 2006 299 305